The 15 1/2-year-old seated in your office is obviously uncomfortable. He has been referred for evaluation by his physician because of decreased growth and failure to develop secondary sexual characteristics, or, as he puts it, "not developing like the other boys."
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.